Anixa Biosciences Inc quarterly report, Q3 FY2014

Business context and reporting period

The supplied filing is ITUS Corporation’s unaudited Form 10-Q for the quarter and nine months ended July 31, 2014; it is not identified as an Anixa Biosciences filing. ITUS focused on acquiring, licensing, and enforcing patent portfolios. The company changed its name to ITUS Corporation on September 2, 2014.

Financial performance and position

Quarterly revenue was entirely a one-time recognition of the remaining $1.187 million under an AU Optronics license arrangement; there was no patent-assertion revenue in the quarter. The resulting quarterly net income included an $850,000 gain from remeasuring derivative liabilities and should not be read as evidence of recurring profitability. Nine-month revenue comprised $1.105 million from patent licenses and settlements and $1.187 million from the AUO arrangement. Nine-month loss per share was $0.03, compared with $0.04 in 2013.

At July 31, cash and cash equivalents were $3.652 million and short-term certificates of deposit were $2.550 million. Operating cash use was $2.017 million, investing cash use was $2.554 million, and financing provided $7.324 million; cash ended the period at $3.652 million. Total liabilities were $13.250 million and shareholders’ equity was $0.150 million. Liabilities included a $5.000 million related-party loan payable, $1.756 million of convertible debentures net of discount, and a $3.137 million patent-acquisition obligation. These July 31 balances preceded the subsequent transactions described below.

Changes versus prior comparable periods

Nine-month revenue rose from zero in 2013, while net loss narrowed from $7.153 million to $6.453 million. Operating expenses fell to $5.772 million from $6.142 million, mainly as marketing, general and administrative expense declined; litigation and licensing costs and patent amortization increased. The nine-month derivative remeasurement changed from a $315,000 gain in 2013 to a $1.461 million loss in 2014. Cash and short-term investments together increased to $6.202 million from $0.898 million at October 31, 2013, supported principally by equity and debt financing.

Outlook, material events and risks

• Management said available cash, short-term investments, receivables, and expected licensing proceeds were expected to fund patent licensing and enforcement activities for at least 12 months. It cautioned that actual cash needs and proceeds could differ; further equity or debt financing might be needed, potentially diluting shareholders, and unavailable funding or insufficient cost reductions could require curtailing or ceasing operations.
• On August 29, ITUS terminated its Videocon relationship and license, canceled mutual $5 million loans, exchanged Videocon depositary receipts for 20 million ITUS shares, and retired those shares. The unaudited pro forma July 31 balance sheet reflecting this and the September debenture transaction showed total assets of $9.248 million, liabilities of $4.442 million, and equity of $4.806 million.
• On September 9, the $3.5 million November 2016 debenture, plus approximately $173,000 accrued interest, was converted into 18.499 million common shares. The holder exchanged 15.979 million of those shares for 3,500 Series A preferred shares, and ITUS retired the exchanged common shares. The filing reports a subsequent conversion/exchange loss of approximately $1.582 million. The preferred stock ranks senior to common stock and has a conditional redemption right payable only from proceeds of a later equity sale.
• A court invalidated two Loyalty Conversion Systems patents on September 3, resulting in dismissal of seven lawsuits; the company said it was evaluating appeal prospects and effects on the portfolio’s other patents. ITUS reported 27 pending patent lawsuits after subsequent events. In the separate AUO/E Ink litigation, the company warned it might not prevail and could owe AUO attorney fees exceeding $1 million. Patent-enforcement actions also carry potential sanctions and fee risks.
• In September, ITUS reported five additional J-Channel license or settlement agreements and filed lawsuits against eBay, Vendio, and Auctiva concerning its Enhanced Auction Technologies portfolio. The filing does not provide the amounts of the September agreements.
• The July registered offering raised $4.0 million gross through 16 million common shares sold at $0.25 per share and included warrants for 8 million shares at $0.40. ITUS reported 216,842,190 common shares outstanding on September 1, 2014.

Most important facts for investors to verify

1. Confirm issuer and reporting-period identity: the provided document names ITUS Corporation and reports a period ended July 31, 2014, not Anixa Biosciences.
2. Review the post-quarter Videocon unwinding, debenture conversion, preferred-stock terms, and pro forma balance sheet; these materially changed reported debt, equity, and share structure.
3. Assess cash burn and the uncertainty of future patent-license receipts against management’s stated 12-month liquidity expectation and potential need for additional financing.
4. Track the invalidated patents, dismissed cases, AUO/E Ink litigation exposure, and the outcomes and economics of pending and newly filed patent matters.
5. Distinguish recurring patent monetization results from the one-time AUO revenue recognition and derivative-liability gains or losses.